Recognizing the oncogenic role of HUWE1 in GBM, researchers have developed an AAV9 dual-vector system for administering dCas9-VP64 to induce endogenous HUWE1 expression in GBM cells, demonstrating promising anti-GBM efficacy [154]. Here, HUWE1 is linked to glioblastoma.